Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer
Abstract We investigated whether the level of bone marrow-derived progenitor cells and mature endothelial cells could be used as predictors of clinical outcome in patients receiving taxotere-based chemotherapy for advanced gastric cancer. Peripheral blood mononuclear cells were obtained from 49 gast...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2008-11, Vol.270 (2), p.269-276 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 276 |
|---|---|
| container_issue | 2 |
| container_start_page | 269 |
| container_title | Cancer letters |
| container_volume | 270 |
| creator | Shin, Sang Joon Jeung, Hei-Cheul Ahn, Joong Bae Rha, Sun Young Yoo, Nae Choon Roh, Jae Kyung Noh, Sung Hoon Chung, Hyun Cheol |
| description | Abstract We investigated whether the level of bone marrow-derived progenitor cells and mature endothelial cells could be used as predictors of clinical outcome in patients receiving taxotere-based chemotherapy for advanced gastric cancer. Peripheral blood mononuclear cells were obtained from 49 gastric cancer patients who received taxotere combined with 5-FU and leucovorin and prophylactic G-CSF treatment. To categorize the cells, the cell markers CD34, vWF, P1H12, and CD31 were stained. Changes in these cells were examined before and after chemotherapy, and the clinical significance of these changes to response prediction and prognosis were investigated. Before the second cycle of chemotherapy, the number of CD34+ /vWF+ and CD34+ cells was higher in non-responders as compared to the responders. Patients with ⩾6.2 CD34+ /vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with |
| doi_str_mv | 10.1016/j.canlet.2008.05.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1505476858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0304383508003856</els_id><sourcerecordid>3242073781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-b582b4d145007a3a3513525b75a02616f6de7fff06949936761416287a09b8a3</originalsourceid><addsrcrecordid>eNqFksFu1DAQhi0EokvhDRCyxBEljGM7cS5IaKEFqYhDe7ccZ9x6m8SLnVQsr8RL4rArVeKCZcmXb_6Z3_8Q8ppByYDV73elNdOAc1kBqBJkCYw9IRummqpoWgVPyQY4iIIrLs_Ii5R2ACBFI5-TM6ZkPi1syO9vofOD_4U93X7i4h21OAyJmnxp58No4j1Gmjv1vjczUhcine-QonPeGnugwVEbxs5PWWE0P_1oBjqHAaOZLNI-JKS5ODPT7KclLIn6yS3JhymD9g7HkOWi2R_-YpfF9vqCpiXeYuborUlz9HbtbzG-JM-cGRK-Or3n5Obi8832S3H1_fLr9uNVYYXgc9FJVXWiZ0ICNIYbLhmXlewaaaCqWe3qHhvnHNStaFteNzUTrK5UY6DtlOHn5O1Rdh_DjwXTrHdhiXncpJlcf7BWUmVKHCkbQ0oRnd7HbD4eNAO9BqR3-hiQXgPSIHUOKJe9OYkv3Yj9Y9EpkQx8OAKYHT54jDpZj9l-7yPaWffB_6_DvwJ28FMOa7jHA6ZHLzpVGvT1uiTrjoAC4ErW_A8Bpric</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505476858</pqid></control><display><type>article</type><title>Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Shin, Sang Joon ; Jeung, Hei-Cheul ; Ahn, Joong Bae ; Rha, Sun Young ; Yoo, Nae Choon ; Roh, Jae Kyung ; Noh, Sung Hoon ; Chung, Hyun Cheol</creator><creatorcontrib>Shin, Sang Joon ; Jeung, Hei-Cheul ; Ahn, Joong Bae ; Rha, Sun Young ; Yoo, Nae Choon ; Roh, Jae Kyung ; Noh, Sung Hoon ; Chung, Hyun Cheol</creatorcontrib><description>Abstract We investigated whether the level of bone marrow-derived progenitor cells and mature endothelial cells could be used as predictors of clinical outcome in patients receiving taxotere-based chemotherapy for advanced gastric cancer. Peripheral blood mononuclear cells were obtained from 49 gastric cancer patients who received taxotere combined with 5-FU and leucovorin and prophylactic G-CSF treatment. To categorize the cells, the cell markers CD34, vWF, P1H12, and CD31 were stained. Changes in these cells were examined before and after chemotherapy, and the clinical significance of these changes to response prediction and prognosis were investigated. Before the second cycle of chemotherapy, the number of CD34+ /vWF+ and CD34+ cells was higher in non-responders as compared to the responders. Patients with ⩾6.2 CD34+ /vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+ /vWF+ /ml (6.0 months, p = 0.076). Patients with ⩾5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046). In an ex vivo pharmacokinetic study, the maximum inhibition ( Imax ) for HUVEC and YCC3 cells was 13.0 ± 6.6% and 74.0 ± 2.0%, respectively. The time to reach Imax ( Tmax ) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells. We suggested that CD34+ /vWF+ and CD34+ cells can be used as a biomarker for prediction and CD34+ cells for prognosis.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2008.05.011</identifier><identifier>PMID: 18555590</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - immunology ; Adenocarcinoma - pathology ; Adult ; Aged ; Angiogenesis ; Antigens, CD34 - analysis ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarker ; Biomarkers ; Biomarkers - analysis ; Bone marrow ; Bone Marrow Cells - drug effects ; Bone Marrow Cells - immunology ; Cancer therapies ; CD34 + cells ; Cell growth ; Cell Line, Tumor ; Cell Movement - drug effects ; Cell Survival - drug effects ; Cells, Cultured ; Disease-Free Survival ; Endothelial Cells - drug effects ; Endothelial Cells - immunology ; Female ; Flow cytometry ; Fluorouracil - administration & dosage ; Gastric cancer ; Granulocyte Colony-Stimulating Factor - administration & dosage ; Hematology, Oncology and Palliative Medicine ; Humans ; Infusions, Intravenous ; Leucovorin - administration & dosage ; Male ; Maximum Tolerated Dose ; Middle Aged ; Patients ; Stem Cells - drug effects ; Stem Cells - immunology ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - immunology ; Stomach Neoplasms - pathology ; Studies ; Taxoids - administration & dosage ; Time Factors ; Treatment Outcome</subject><ispartof>Cancer letters, 2008-11, Vol.270 (2), p.269-276</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2008 Elsevier Ireland Ltd</rights><rights>Copyright Elsevier Limited Nov 8, 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-b582b4d145007a3a3513525b75a02616f6de7fff06949936761416287a09b8a3</citedby><cites>FETCH-LOGICAL-c443t-b582b4d145007a3a3513525b75a02616f6de7fff06949936761416287a09b8a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304383508003856$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18555590$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shin, Sang Joon</creatorcontrib><creatorcontrib>Jeung, Hei-Cheul</creatorcontrib><creatorcontrib>Ahn, Joong Bae</creatorcontrib><creatorcontrib>Rha, Sun Young</creatorcontrib><creatorcontrib>Yoo, Nae Choon</creatorcontrib><creatorcontrib>Roh, Jae Kyung</creatorcontrib><creatorcontrib>Noh, Sung Hoon</creatorcontrib><creatorcontrib>Chung, Hyun Cheol</creatorcontrib><title>Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Abstract We investigated whether the level of bone marrow-derived progenitor cells and mature endothelial cells could be used as predictors of clinical outcome in patients receiving taxotere-based chemotherapy for advanced gastric cancer. Peripheral blood mononuclear cells were obtained from 49 gastric cancer patients who received taxotere combined with 5-FU and leucovorin and prophylactic G-CSF treatment. To categorize the cells, the cell markers CD34, vWF, P1H12, and CD31 were stained. Changes in these cells were examined before and after chemotherapy, and the clinical significance of these changes to response prediction and prognosis were investigated. Before the second cycle of chemotherapy, the number of CD34+ /vWF+ and CD34+ cells was higher in non-responders as compared to the responders. Patients with ⩾6.2 CD34+ /vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+ /vWF+ /ml (6.0 months, p = 0.076). Patients with ⩾5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046). In an ex vivo pharmacokinetic study, the maximum inhibition ( Imax ) for HUVEC and YCC3 cells was 13.0 ± 6.6% and 74.0 ± 2.0%, respectively. The time to reach Imax ( Tmax ) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells. We suggested that CD34+ /vWF+ and CD34+ cells can be used as a biomarker for prediction and CD34+ cells for prognosis.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Angiogenesis</subject><subject>Antigens, CD34 - analysis</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarker</subject><subject>Biomarkers</subject><subject>Biomarkers - analysis</subject><subject>Bone marrow</subject><subject>Bone Marrow Cells - drug effects</subject><subject>Bone Marrow Cells - immunology</subject><subject>Cancer therapies</subject><subject>CD34 + cells</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>Cell Movement - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Cells, Cultured</subject><subject>Disease-Free Survival</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - immunology</subject><subject>Female</subject><subject>Flow cytometry</subject><subject>Fluorouracil - administration & dosage</subject><subject>Gastric cancer</subject><subject>Granulocyte Colony-Stimulating Factor - administration & dosage</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Leucovorin - administration & dosage</subject><subject>Male</subject><subject>Maximum Tolerated Dose</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Stem Cells - drug effects</subject><subject>Stem Cells - immunology</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - immunology</subject><subject>Stomach Neoplasms - pathology</subject><subject>Studies</subject><subject>Taxoids - administration & dosage</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksFu1DAQhi0EokvhDRCyxBEljGM7cS5IaKEFqYhDe7ccZ9x6m8SLnVQsr8RL4rArVeKCZcmXb_6Z3_8Q8ppByYDV73elNdOAc1kBqBJkCYw9IRummqpoWgVPyQY4iIIrLs_Ii5R2ACBFI5-TM6ZkPi1syO9vofOD_4U93X7i4h21OAyJmnxp58No4j1Gmjv1vjczUhcine-QonPeGnugwVEbxs5PWWE0P_1oBjqHAaOZLNI-JKS5ODPT7KclLIn6yS3JhymD9g7HkOWi2R_-YpfF9vqCpiXeYuborUlz9HbtbzG-JM-cGRK-Or3n5Obi8832S3H1_fLr9uNVYYXgc9FJVXWiZ0ICNIYbLhmXlewaaaCqWe3qHhvnHNStaFteNzUTrK5UY6DtlOHn5O1Rdh_DjwXTrHdhiXncpJlcf7BWUmVKHCkbQ0oRnd7HbD4eNAO9BqR3-hiQXgPSIHUOKJe9OYkv3Yj9Y9EpkQx8OAKYHT54jDpZj9l-7yPaWffB_6_DvwJ28FMOa7jHA6ZHLzpVGvT1uiTrjoAC4ErW_A8Bpric</recordid><startdate>20081108</startdate><enddate>20081108</enddate><creator>Shin, Sang Joon</creator><creator>Jeung, Hei-Cheul</creator><creator>Ahn, Joong Bae</creator><creator>Rha, Sun Young</creator><creator>Yoo, Nae Choon</creator><creator>Roh, Jae Kyung</creator><creator>Noh, Sung Hoon</creator><creator>Chung, Hyun Cheol</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20081108</creationdate><title>Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer</title><author>Shin, Sang Joon ; Jeung, Hei-Cheul ; Ahn, Joong Bae ; Rha, Sun Young ; Yoo, Nae Choon ; Roh, Jae Kyung ; Noh, Sung Hoon ; Chung, Hyun Cheol</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-b582b4d145007a3a3513525b75a02616f6de7fff06949936761416287a09b8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Angiogenesis</topic><topic>Antigens, CD34 - analysis</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarker</topic><topic>Biomarkers</topic><topic>Biomarkers - analysis</topic><topic>Bone marrow</topic><topic>Bone Marrow Cells - drug effects</topic><topic>Bone Marrow Cells - immunology</topic><topic>Cancer therapies</topic><topic>CD34 + cells</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>Cell Movement - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Cells, Cultured</topic><topic>Disease-Free Survival</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - immunology</topic><topic>Female</topic><topic>Flow cytometry</topic><topic>Fluorouracil - administration & dosage</topic><topic>Gastric cancer</topic><topic>Granulocyte Colony-Stimulating Factor - administration & dosage</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Leucovorin - administration & dosage</topic><topic>Male</topic><topic>Maximum Tolerated Dose</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Stem Cells - drug effects</topic><topic>Stem Cells - immunology</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - immunology</topic><topic>Stomach Neoplasms - pathology</topic><topic>Studies</topic><topic>Taxoids - administration & dosage</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shin, Sang Joon</creatorcontrib><creatorcontrib>Jeung, Hei-Cheul</creatorcontrib><creatorcontrib>Ahn, Joong Bae</creatorcontrib><creatorcontrib>Rha, Sun Young</creatorcontrib><creatorcontrib>Yoo, Nae Choon</creatorcontrib><creatorcontrib>Roh, Jae Kyung</creatorcontrib><creatorcontrib>Noh, Sung Hoon</creatorcontrib><creatorcontrib>Chung, Hyun Cheol</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shin, Sang Joon</au><au>Jeung, Hei-Cheul</au><au>Ahn, Joong Bae</au><au>Rha, Sun Young</au><au>Yoo, Nae Choon</au><au>Roh, Jae Kyung</au><au>Noh, Sung Hoon</au><au>Chung, Hyun Cheol</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2008-11-08</date><risdate>2008</risdate><volume>270</volume><issue>2</issue><spage>269</spage><epage>276</epage><pages>269-276</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Abstract We investigated whether the level of bone marrow-derived progenitor cells and mature endothelial cells could be used as predictors of clinical outcome in patients receiving taxotere-based chemotherapy for advanced gastric cancer. Peripheral blood mononuclear cells were obtained from 49 gastric cancer patients who received taxotere combined with 5-FU and leucovorin and prophylactic G-CSF treatment. To categorize the cells, the cell markers CD34, vWF, P1H12, and CD31 were stained. Changes in these cells were examined before and after chemotherapy, and the clinical significance of these changes to response prediction and prognosis were investigated. Before the second cycle of chemotherapy, the number of CD34+ /vWF+ and CD34+ cells was higher in non-responders as compared to the responders. Patients with ⩾6.2 CD34+ /vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+ /vWF+ /ml (6.0 months, p = 0.076). Patients with ⩾5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046). In an ex vivo pharmacokinetic study, the maximum inhibition ( Imax ) for HUVEC and YCC3 cells was 13.0 ± 6.6% and 74.0 ± 2.0%, respectively. The time to reach Imax ( Tmax ) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells. We suggested that CD34+ /vWF+ and CD34+ cells can be used as a biomarker for prediction and CD34+ cells for prognosis.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>18555590</pmid><doi>10.1016/j.canlet.2008.05.011</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2008-11, Vol.270 (2), p.269-276 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_journals_1505476858 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - immunology Adenocarcinoma - pathology Adult Aged Angiogenesis Antigens, CD34 - analysis Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarker Biomarkers Biomarkers - analysis Bone marrow Bone Marrow Cells - drug effects Bone Marrow Cells - immunology Cancer therapies CD34 + cells Cell growth Cell Line, Tumor Cell Movement - drug effects Cell Survival - drug effects Cells, Cultured Disease-Free Survival Endothelial Cells - drug effects Endothelial Cells - immunology Female Flow cytometry Fluorouracil - administration & dosage Gastric cancer Granulocyte Colony-Stimulating Factor - administration & dosage Hematology, Oncology and Palliative Medicine Humans Infusions, Intravenous Leucovorin - administration & dosage Male Maximum Tolerated Dose Middle Aged Patients Stem Cells - drug effects Stem Cells - immunology Stomach Neoplasms - drug therapy Stomach Neoplasms - immunology Stomach Neoplasms - pathology Studies Taxoids - administration & dosage Time Factors Treatment Outcome |
| title | Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T17%3A08%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mobilized%20CD34+%20cells%20as%20a%20biomarker%20candidate%20for%20the%20efficacy%20of%20combined%20maximal%20tolerance%20dose%20and%20continuous%20infusional%20chemotherapy%20and%20G-CSF%20surge%20in%20gastric%20cancer&rft.jtitle=Cancer%20letters&rft.au=Shin,%20Sang%20Joon&rft.date=2008-11-08&rft.volume=270&rft.issue=2&rft.spage=269&rft.epage=276&rft.pages=269-276&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2008.05.011&rft_dat=%3Cproquest_cross%3E3242073781%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505476858&rft_id=info:pmid/18555590&rft_els_id=1_s2_0_S0304383508003856&rfr_iscdi=true |